The company told the American Diabetes Association the metabolic monitor could reduce down-the-line healthcare costs for T2 non-insulin users and others. "These trends have to change," says CEO Kevin Sayer.
Subscribe to:
Post Comments (Atom)
< + > Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI – Life Sciences Today Podcast Episode 41
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, ...
No comments:
Post a Comment